The authors noted that right-sided EA is often misdiagnosed as acute appendicitis, and that steady but sharp and nonmigratory pain in either of the lower abdominal quadrants should raise suspicion of EA.
Epiploic appendagitis may be causing that abdominal pain | Image Credit: Contemporary Pediatrics
In a recent case report, a group of physicians in India describe an 11-year-old boy who came to their hospital’s emergency department with acute onset, constant sharp abdominal pain localized to the right lower quadrant. An ultrasound indicated a normal appendix despite probe tenderness, whereas CT showed an oval fat-attenuated lesion on the right antimesenteric border of the colon, which is characteristic of epiploic appendagitis (EA). The patient was prescribed ibuprofen and antiemetics and experienced complete remission of symptoms. He remained asymptomatic at 2 weeks follow-up.
The authors noted that right-sided EA is often misdiagnosed as acute appendicitis, and that steady but sharp and nonmigratory pain in either of the lower abdominal quadrants should raise suspicion of EA. Although ultrasonography is the diagnostic entity of choice, its sensitivity is low and it is operator dependent. As a result, abdominal CT, with its potential for pathognomonic findings, is the most widely used imaging tool for EA.
This condition is new to me. Add this to mesenteric adenitis, among others, in your differential of acute right-lower abdominal pain, and you may be able to spare some children from exploratory surgery—albeit at the cost of a CT scan—when the ultrasound is inconclusive.
For more from the August, 2023 issue of Contemporary Pediatrics®, click here.
Reference:
Rustogi D, Khare C, Kumar K. Epiploic appendagitis: not so unusual cause of pediatric abdominal pain. Int J Pediatr Adolesc Med.2022;9(4):225-226. doi:10.1016/j.ijpam.2023.01.001
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
June 25th 2025Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.